-
MSD withdraws EU application of Keytruda combination for the treatment of NSCLC
pharmafile
October 31, 2017
MSD has been forced to withdraw its EU marketing application for Keytruda (pembrolizumab) in combination with pemetrexed and carboplatin as a first-line treatment for metastatic non-squamous non-small cell lung cancer (NSCLC),
-
Merck announces findings from Phase III study of KEYTRUDA
expressbpd
September 14, 2017
The findings include updated survival data showing a 19 per cent reduction in the risk of death over standard treatment in the intent-to-treat population
-
EC approves for Merck's Keytruda for bladder cancer indication
pharmatimes
September 07, 2017
The European Commission has approved Merck & Co's Keytruda (pembrolizumab), the company’s anti-PD-1 therapy, for the treatment of certain patients with locally advanced or metastatic urothelial carcinoma, a type of bladder cancer.
-
Medivir Initiates Study of Birinapant in Combination with KEYTRUDA
americanpharmaceuticalreview
August 21, 2017
Medivir announced the first patient has been enrolled in the company's phase I/II study of birinapant?in combination with the anti-PD-1 therapy KEYTRUDA (pembrolizumab), which is marketed by MSD. The objectives of the study are to evaluate the safety, tol
-
NICE leans towards a ‘no’ for Keytruda in urothelial cancer
pharmatimes
August 07, 2017
Cost regulators for NHS therapies in England and Wales have turned down MSD’s immunotherapy Keytruda as a treatment for locally advanced or metastatic urothelial cancer.
-
Latest Progress of PD-1 Inhibitors: Keytruda and Opdivo are close
en-cphi.cn
August 04, 2017
There is a subtle change in the competition situation of PD-1/PD-L1 market, the gap between Keytruda and Opdivo being significantly decreasing, becoming the main impetus to drive the rapid expansion of the entire PD-1/PD-L1 drug market.
-
Mercks new Keytruda flat dose could add $1B each year to U.S. healthcare spending
fiercepharma
July 24, 2017
While some drug price hikes in the hundreds or thousands of percentages appear to be purely about profit and generate plenty of criticism, a new paper in the Journal of the National Cancer Institute highlights another lucrative strategy for drugmakers tha
-
Merck's Keytruda speeds its I-O market-share grab as Bristol-Myers' Opdivo declines
fiercepharma
July 21, 2017
The latest immuno-oncology market-share numbers are out, and they show that Merck & Co.’s Keytruda is not only gaining on Bristol-Myers Squibb archrival Opdivo, but it’s picked up the pace, too.
-
Kitov Announces Results of Study Demonstrating NT-219 Enhanced Efficacy of Keytruda
americanpharmaceuticalreview
July 20, 2017
Kitov Pharmaceuticals announced results of a pre-clinical study demonstrating that NT-219, the lead drug candidate of its subsidiary TyrNovo, in combination with Keytruda...
-
First patients treated in Phase I/II trial of NOX-A12 combined with Keytruda in metastatic pancreati
cphi-online
July 06, 2017
NOX-A12 has the potential to transform cancer types that are resistant to checkpoint inhibitor therapy into checkpoint inhibitor sensitive tumours
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight January 2025
